Lupus Nephritis Treatment Guidelines

Introduction to Treatment

The American College of Nephrology recommends avoiding NSAIDs in lupus nephritis patients due to nephrotoxicity risk, while cytotoxic therapy combined with glucocorticoids forms the cornerstone of treatment for active proliferative disease 1

Acetaminophen should be used as the first-line analgesic for pain control in lupus nephritis patients 3
Low-dose glucocorticoids provide anti-inflammatory effects that help with lupus-related pain 1
Hydroxychloroquine is universally recommended and provides disease-modifying effects that reduce overall disease activity and pain 2, 4

For active proliferative lupus nephritis, glucocorticoids must be combined with one of the following cytotoxic/immunosuppressive agents: mycophenolate mofetil, low-dose intravenous cyclophosphamide, triple therapy with voclosporin, or belimumab-containing regimens, all with a Grade 1B recommendation 1
Mycophenolate mofetil is the first choice for most patients with Class III/IV lupus nephritis, particularly those concerned about fertility preservation 1, 3

The glucocorticoid component consists of methylprednisolone IV for 1-3 days, followed by oral prednisone, and tapering over several months to the lowest maintenance dose 1

Choose initial cytotoxic therapy based on factors such as disease severity, fertility concerns, and adverse prognostic factors 1

After achieving response with induction therapy, continue maintenance for at least 3 years with lower-dose mycophenolate mofetil or azathioprine plus low-dose prednisone 6, 3
Belimumab can be continued for up to 2.5 years as part of maintenance 1, 7

Assess response at defined intervals, with a ≥25% reduction in proteinuria by 3 months, ≥50% reduction by 6 months, and proteinuria <0.5-0.7 g/g by 12 months 2, 4, 3

Cyclophosphamide toxicity includes gonadal toxicity and hemorrhagic cystitis risk, which can be minimized with low-dose regimens and adequate hydration 1
Calcineurin inhibitor use requires cautious dosing, particularly in patients with eGFR <45 ml/min/1.73 m², and close monitoring of serum creatinine 1, 6, 5
Belimumab can be used if eGFR ≥30 ml/min/1.73 m², and is more effective with proteinuria <3 g/day at baseline 1